dc.contributor.author | Aravantinos, Gerasimos | en |
dc.contributor.author | Bafaloukos, Dimitrios | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Christodoulou, C. | en |
dc.contributor.author | Papadimitriou, C. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Kalofonos, H. P. | en |
dc.contributor.author | Gogas, H. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.contributor.author | Dimopoulos, M. A. | en |
dc.creator | Aravantinos, Gerasimos | en |
dc.creator | Bafaloukos, Dimitrios | en |
dc.creator | Fountzilas, George | en |
dc.creator | Christodoulou, C. | en |
dc.creator | Papadimitriou, C. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Kalofonos, H. P. | en |
dc.creator | Gogas, H. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.creator | Dimopoulos, M. A. | en |
dc.date.accessioned | 2018-06-22T09:52:29Z | |
dc.date.available | 2018-06-22T09:52:29Z | |
dc.date.issued | 2003 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41377 | |
dc.description.abstract | Background: This multicenter, prospective phase II study evaluated the safety and efficacy of the combination of docetaxel and vinorelbine in patients with platinum-resistant, paclitaxel-pretreated recurrent ovarian cancer. Patients and methods: Treatment consisted of vinorelbine 25 mg/m2 as a 20-min i.v. infusion (days 1 and 8), and docetaxel 70 mg/m2, as a 1-h i.v. infusion (day 8). Granulocyte colony-stimulating factor support was administered prophylactically on days 12-16. Treatment was repeated every 21 days. Results: Forty-six patients were enrolled. The median number of previous chemotherapeutic regimens was one (range 1-3) with a median treatment-free interval of 4.3 months. Four chemotherapy cycles per patient were administered. Almost 75% of the planned doses for both drugs were given. Forty-one patients are evaluable for response. Three patients (6.5% of all patients; 7.3% of evaluable patients) achieved complete response and eight (17.4% and 19.5%, respectively) a partial response to chemotherapy leading to overall response rates of 23.9% and 26.8%, respectively. Another 34.8% (39.0%) had stable disease. At a median follow-up of 30 months, the median disease-free survival was 13 months, relapse-free survival was 5 months, time to progression was 4.5 months, and overall survival was 9.3 months. Severe toxicities included leukopenia (31%), neutropenia (35%) and febrile neutropenia (20%). Conclusions: The combination of docetaxel/vinorelbine is an effective regimen with manageable toxicity for the treatment of platinum-resistant, paclitaxel-pretreated ovarian cancer. | en |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Doxorubicin | en |
dc.subject | Etoposide | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Cancer survival | en |
dc.subject | Carboplatin | en |
dc.subject | Chemotherapy | en |
dc.subject | Disease progression | en |
dc.subject | Follow up | en |
dc.subject | Neoplasm | en |
dc.subject | Ovarian cancer | en |
dc.subject | Ovarian neoplasms | en |
dc.subject | Ovary cancer | en |
dc.subject | Paclitaxel | en |
dc.subject | Platinum derivative | en |
dc.subject | Priority journal | en |
dc.subject | Abdominal pain | en |
dc.subject | Alopecia | en |
dc.subject | Anemia | en |
dc.subject | Anorexia | en |
dc.subject | Antiemetic agent | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Arthralgia | en |
dc.subject | Bone marrow suppression | en |
dc.subject | Cancer recurrence | en |
dc.subject | Cisplatin | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Constipation | en |
dc.subject | Controlled clinical trial | en |
dc.subject | Diarrhea | en |
dc.subject | Disease-free survival | en |
dc.subject | Docetaxel | en |
dc.subject | Drug choice | en |
dc.subject | Drug effect | en |
dc.subject | Drug efficacy | en |
dc.subject | Drug infusion | en |
dc.subject | Drug resistance | en |
dc.subject | Drug resistance | en |
dc.subject | Drug safety | en |
dc.subject | Fatigue | en |
dc.subject | Febrile neutropenia | en |
dc.subject | Gemcitabine | en |
dc.subject | Granulocyte colony-stimulating factor | en |
dc.subject | Infection | en |
dc.subject | Leukopenia | en |
dc.subject | Local | en |
dc.subject | Methylprednisolone | en |
dc.subject | Monotherapy | en |
dc.subject | Mucosa inflammation | en |
dc.subject | Multicenter study | en |
dc.subject | Myalgia | en |
dc.subject | Nausea and vomiting | en |
dc.subject | Navelbine | en |
dc.subject | Neoplasm recurrence | en |
dc.subject | Neurotoxicity | en |
dc.subject | Neutropenia | en |
dc.subject | Ondansetron | en |
dc.subject | Oxaliplatin | en |
dc.subject | Phase 2 clinical trial | en |
dc.subject | Phytogenic | en |
dc.subject | Platinum-resistant | en |
dc.subject | Prospective studies | en |
dc.subject | Recombinant granulocyte colony stimulating factor | en |
dc.subject | Skin disease | en |
dc.subject | Stomatitis | en |
dc.subject | Taxane derivative | en |
dc.subject | Taxoids | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Topotecan | en |
dc.subject | Treatment outcome | en |
dc.subject | Vertigo | en |
dc.subject | Vinblastine | en |
dc.subject | Vinorelbine | en |
dc.title | Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1093/annonc/mdg292 | |
dc.description.volume | 14 | |
dc.description.issue | 7 | |
dc.description.startingpage | 1094 | |
dc.description.endingpage | 1099 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Aravantinos, Gerasimos [0000-0002-2106-1713] | |
dc.contributor.orcid | Kalofonos, H. P. [0000-0002-3286-778X] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-2106-1713 | |
dc.gnosis.orcid | 0000-0002-3286-778X | |